Revlimid and Salivary hypersecretion - a phase IV clinical study of FDA data

Summary:

Salivary hypersecretion is reported as a side effect among people who take Revlimid (lenalidomide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Myelodysplastic syndrome.

The phase IV clinical study analyzes which people have Salivary hypersecretion when taking Revlimid. It is created by eHealthMe based on reports of 377,717 people who have side effects when taking Revlimid from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 779 drugs and 1,338 conditions by eHealthMe. Check the latest studies of Salivary hypersecretion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

377,717 people reported to have side effects when taking Revlimid.
Among them, 48 people (0.01%) have Salivary hypersecretion.

Could Revlimid cause Salivary hypersecretion?

Among these 48 people:

How long have people been on Revlimid when they have Salivary hypersecretion? *

What is the gender of people who have Salivary hypersecretion when taking Revlimid? *

female: 41.67 %
male: 58.33 %

What is the age of people who have Salivary hypersecretion when taking Revlimid? *

What are other drugs people take besides Revlimid? *

What are other side effects people have besides Salivary hypersecretion? *

Nausea (feeling of having an urge to vomit): 11 people, 22.92%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 14.58%
Diarrhea: 7 people, 14.58%
Fatigue (feeling of tiredness): 6 people, 12.50%
Nausea And Vomiting: 5 people, 10.42%
Chest Pain: 4 people, 8.33%
Weakness: 3 people, 6.25%
Peripheral Swelling: 3 people, 6.25%
Dizziness: 3 people, 6.25%
Dyspnea (difficult or laboured breathing): 3 people, 6.25%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 6.25%
Breast Cancer: 2 people, 4.17%
Respiratory Disorder (respiratory disease): 1 person, 2.08%
Prostatic Disorder: 1 person, 2.08%
Hypersensitivity: 1 person, 2.08%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 1 person, 2.08%
High Blood Pressure: 1 person, 2.08%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 2.08%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 2.08%
Depression: 1 person, 2.08%

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Salivary hypersecretion?

- Check whether Salivary hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Revlimid:

Revlimid (378,026 reports)

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Salivary hypersecretion:

Salivary hypersecretion (779 drugs)

Browse all the conditions that are associated with Salivary hypersecretion:

Salivary hypersecretion (1,338 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.